Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s products portfolio comprise Acetadote injection for the treatment of acetaminophen poisoning; Caldolor injection for the treatment for pain and fever; Kristalose, a prescription laxative for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and related duodenal ulcer diseases; Vaprisol injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. Its products portfolio also include Hepatoren injection, which is in Phase II clinical trials for the treatment of critically ill hospitalized patients suffering from liver and kidney failure associated with hepatorenal syndrome; and Boxaban oral capsules that is in Phase II clinical trials for the treatment of patients with aspirin-exacerbated respiratory disease. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.